SCHEMBL2903266

SCHEMBL2903266

Fc1ccc(-c2ccc(C(c3c[nH]nc3-c3ccco3)N3CCOCC3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 3/20 0.41
ACHE P22303 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LMNA P02545 3/20 0.37
MAPT P10636 3/20 0.37
PKM P14618 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 1/20 0.35
STK4 Q13043 1/20 0.35
STK3 Q13188 1/20 0.35
LRRK2 Q5S007 1/20 0.35
PIK3R1 P27986 1/20 0.34
PIK3CA P42336 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902613 0.91 PIK3R1 (0.37) P4HBACHEHRH3LMNAMAPT
SCHEMBL2904844 0.90 OPRD1 (0.40) P4HBLMNAMAPTPOLBPIK3R1
SCHEMBL2908995 0.88 BRAF (0.46) P4HBLMNAMAPTPOLBALDH1A1
SCHEMBL2902824 0.87 MAPT (0.47) LMNAMAPTPOLBALDH1A1NPSR1
SCHEMBL2905003 0.85 SIRT1 (0.38) P4HBLMNAMAPTPKMPOLB
SCHEMBL2909335 0.85 HRH3 (0.43) P4HBACHEHRH3LMNAMAPT
SCHEMBL2905980 0.85 ALDH1A1 (0.42) LMNAMAPTPKMPOLBALDH1A1
Morpholine SCHEMBL2905731 0.84 OPRD1 (0.35) P4HBLMNAMAPTPOLBSTK4
SCHEMBL2907737 0.84 LMNA (0.33) P4HBLMNAMAPTPOLBALDH1A1
SCHEMBL2903067 0.82 OPRD1 (0.37) P4HBHRH3PIK3R1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A P4HB 4026/4885ACHE 892/4885HRH3 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.